Business
NetScientific Portfolio Update
NetScientific Portfolio Update.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 9458B NetScientific PLC 16 January 2018 \n\nNetScientific Portfolio Update \n \nLondon, UK - 16 January 2018 - NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, today announces an update on its core portfolio. Over 2018 NetScientific will continue the commercial and corporate development of all its portfolio assets to maximise value. \nGlycotest:\n· Glycotest successfully completed a clinical evaluation of its HCC Panel for Hepatocellular Carcinoma (HCC), the most common form of liver cancer.\n· Glycotest continues to work with its potential partner and expects to close the Series A within Q1 2018.\n· Glycotest has begun planning for a further clinical validation study and to move into the commercial phase, aiming to make its first sale.\n· Glycotest plans to sign a service agreement with a CLIA lab with the goal of commercialising its HCC Panel test as a clinical lab testing service in the U.S.\n \nVortex Biosciences:\n· Vortex is focused on clinical assay development and beginning clinical research studies utilising existing assays optimised for use with CTCs, targeting lung cancer diagnostics. These include EGFR mutation analysis, PDL-1 expression analysis and ALK FISH.\n· Vortex expects to make these assays available for use with the output of the VTX-1 system during 2018.\n· Vortex is also aiming to develop partnerships with leading diagnostic companies targeting the introduction of clinical assays using novel biomarkers. \n· Vortex has placed three VTX-1 Liquid Biopsy Systems into leading oncology institutions' research facilities, and will continue to sell into the research market.\n· Vortex continues to build relationships with commercial partners and investors in advance of targeting a Series A fundraise or commercial partnership towards the end of H2 2018.\n \nProAxsis:\n· ProAxsis has expanded its contract with Diagenics, which is currently selling the Neutrophil Elastase Immunoassay (NEIA), as the distribution partner for the recently launched CE Marked Plasmin Immunoassay across the UK and Ireland. \n·&nbs...